Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for depression, anxiety, circadian and sleep disturbances after acute myocardial syndrome
2015-002116-32Phase 3Completed
- Sponsor
- Zealand University Hospital
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in major depressive disorder (MDD), anxiety disorder, circadian rhythm sleep disorder (CRSD) and 1 more, sponsored by Zealand University Hospital. Primary endpoint: Primary effect parameter. Started Aug 2015; status: completed.
02
Drugs
melatonin
03
Conditions
major depressive disorder (MDD)anxiety disordercircadian rhythm sleep disorder (CRSD)sleep disorder
Beyond the preview
Go deeper on 2015-002116-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002116-32.